Wedbush analyst Liana Moussatos attributes yesterday's selloff in Intercept shares to a patient death in the CONTROL trial, but this death was not considered to be drug-related by the investigator nor by the data safety monitory board, she tells investors. Given that the death was "unrelated" to the trial, she views the selloff as unwarranted and overdone, presenting a buying opportunity. Citing the success in the AESOP Phase 2 trial, Moussatos is now including $22 per share value for potential future sales of Ocaliva for PSC and has increased her price target on Intercept to $253 from $231. She keeps an Outperform rating on the stock.